Adipose tissue

ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications

Retrieved on: 
Wednesday, February 28, 2024

Pyroptosis results in systemic release of inflammatory cytokines, IL-1β and IL-18, and ASC specks, which perpetuates and spreads inflammation to other tissues leading to the metabolic disturbances associated with obesity.

Key Points: 
  • Pyroptosis results in systemic release of inflammatory cytokines, IL-1β and IL-18, and ASC specks, which perpetuates and spreads inflammation to other tissues leading to the metabolic disturbances associated with obesity.
  • ZyVersa is developing Inflammasome ASC Inhibitor IC 100, designed to inhibit formation of multiple types of inflammasomes and their associated ASC specks to attenuate initiation and perpetuation of damaging inflammation.
  • WESTON, Fla., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights data published in Nature reinforcing IC 100’s rationale for inhibiting ASC and ASC Specks to attenuate damaging inflammation associated with various conditions, including obesity and its complications.
  • Likewise, IC 100 uniquely inhibits ASC specks to attenuate spread and perpetuation of damaging inflammation.” To review a white paper summarizing the mechanism of action and preclinical data for IC 100, Click Here .

WAYLIVRA (volanesorsen): An Antisense Oligonucleotide Inhibitor of Apolipoprotein CIII (apoCIII) mRNA - Market Size, Forecasts, and Emerging Insights, 2019-2023 and 2024-2032 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024

Further, it also consists of future market assessments inclusive of the WAYLIVRA market forecast analysis for lipodystrophy in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in lipodystrophy.

Key Points: 
  • Further, it also consists of future market assessments inclusive of the WAYLIVRA market forecast analysis for lipodystrophy in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in lipodystrophy.
  • WAYLIVRA (volanesorsen), an antisense oligonucleotide inhibitor of apolipoprotein CIII (apoCIII) mRNA, is being developed by Ionis Pharmaceuticals through its subsidiary company, Akcea Therapeutics to treat familial partial lipodystrophy (FPL).
  • Volanesorsen is an antisense oligonucleotide that binds to apoC-III mRNA, leading to its degradation and preventing the translation of apoC-III protein.
  • What are the other emerging products available and how are these giving competition to WAYLIVRA for lipodystrophy?

Quolet announces completion of Phase 1 healthy volunteer study evaluating the safety and bioavailability of Cannabidiol in a novel formulation intended for treatment of various neurological and psychiatric diseases

Retrieved on: 
Thursday, February 22, 2024

Quolet , a private clinical stage biopharmaceutical company, is announcing the completion of a Phase 1 healthy volunteer study evaluating pure Cannabidiol (CBD) ( clinicaltrials.gov NCT05032807 ).

Key Points: 
  • Quolet , a private clinical stage biopharmaceutical company, is announcing the completion of a Phase 1 healthy volunteer study evaluating pure Cannabidiol (CBD) ( clinicaltrials.gov NCT05032807 ).
  • Researchers at King’s College London partnered with the SEEK group to test whether its bioavailability could be improved by administering CBD in a novel patented lipid formulation.
  • This lipid formulation allows high doses of CBD (200mg) to be administered in capsules including only GRAS and/or pharmaceutical approved ingredients.
  • In one visit they were given the lipid-CBD, and in the other visit they were given standard CBD-only formulation.

Celluma Light Therapy Announces Launch of Revolutionary Body Contouring Device

Retrieved on: 
Friday, March 1, 2024

TUSTIN, Calif., March 1, 2024 /PRNewswire/ -- BioPhotas, Inc., the market leader in therapeutic LED Light Therapy Devices, announced today the launch of the Celluma CONTOUR, the only FDA-cleared light therapy device treating body contouring, aging skin, and pain management.

Key Points: 
  • TUSTIN, Calif., March 1, 2024 /PRNewswire/ -- BioPhotas, Inc., the market leader in therapeutic LED Light Therapy Devices, announced today the launch of the Celluma CONTOUR, the only FDA-cleared light therapy device treating body contouring, aging skin, and pain management.
  • "The Celluma CONTOUR is the first LED Light Therapy device to be FDA-cleared on an Over-The-Counter basis for body contouring," commented BioPhotas President and CEO, Curtis Cluff.
  • "It is also the only LED light therapy device on the market designed with multiple treatment modes for reducing wrinkles, reducing muscle and joint pain, as well as body contouring in a single device."
  • Low Level Light Therapy (LLLT) for body contouring is a proven, non-invasive technique to reduce the circumference of the hips, waist, and thighs safely and effectively.

MelliCell Announces Dr. Fatima Cody Stanford as New Advisory Board Member

Retrieved on: 
Tuesday, February 27, 2024

This strategic move aligns with MelliCell's mission to revolutionize the treatment and understanding of metabolic diseases through advanced fat cell research.

Key Points: 
  • This strategic move aligns with MelliCell's mission to revolutionize the treatment and understanding of metabolic diseases through advanced fat cell research.
  • Dr. Stanford brings to MelliCell a rich legacy of expertise in obesity medicine as an Associate Professor of Medicine and Pediatrics at Massachusetts General Hospital (MGH) / Harvard Medical School (HMS).
  • As MelliCell prepares for its upcoming funding round, the addition of Dr. Stanford to the advisory board marks a pivotal moment in the company's trajectory towards establishing new standards in metabolic disease treatment.
  • "Joining MelliCell's dynamic team is an exciting opportunity to advance the fight against obesity through our focused research on adipose tissue," expressed Dr. Stanford.

Reflection paper on investigation of pharmacokinetics in the obese population - Scientific guideline

Retrieved on: 
Wednesday, February 14, 2024

Reflection paper on investigations of pharmacokinetics in

Key Points: 
    • Reflection paper on investigations of pharmacokinetics in
      the obese population
      Table of contents
      1.
    • References .............................................................................................. 9

      Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 2/12

      1.

    • This is considered
      a shortcoming that is potentially compounded by obese patients often being poorly represented in
      clinical studies.
    • The specific aims of this reflection paper are to:
      ?

      describe how the effects of obesity can be investigated during clinical medicinal product
      development.

    • ?

      provide recommendations on when investigations of the effect of obesity on the PK of a
      medicinal product should be particularly considered.

    • Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 3/12

      ?

      discuss how to reflect PK (and/or PK/PD) findings in weight/weight-based dosing
      recommendations.

    • Absorption
      Reduced rate of absorption linked to locally reduced blood flow (8) is reported for the subcutaneous
      and transdermal routes in obese subjects.
    • Distribution
      The distribution of medicinal products is driven by body composition, regional blood flow and binding to
      tissue and plasma proteins.
    • Obese subjects have a larger absolute lean body weight (LBW) as well as fat mass.
    • The physicochemical properties of a medicinal product (lipophilicity, polarity, molecular size, and
      degree of ionization) influence its distribution in the body.
    • In BMI class III obese
      subjects, the blood flow per gram of fat is significantly lower than that observed in class I obese or
      lean subjects (4).
    • Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 4/12

      An increased amount of alpha-1-acid-glycoprotein (AAG), linked to a chronic inflammatory state, is
      reported in obese individuals.

    • Fatty infiltrations are present in the liver for 90% of obese subjects, with the extent of the infiltrations
      being proportional to the degree of obesity.
    • In some cases, in particular for CYP3A4 metabolized medicinal products,
      bodyweight normalized clearance can be lower in obese patients (23).
    • Based on presently available data, it has been suggested that uptake transporters

      Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 5/12

      are downregulated while efflux transporters may be upregulated (31).

    • Platelet hyper-reactivity is also observed,
      which can impair the response to anti-platelet medicinal products in obese patients (42, 43).
    • Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 6/12

      3.

      the medicinal product properties and scientific literature indicate that obesity may lead to a
      marked effect on elimination and/or distribution or on the PK/PD relationship.

    • These
      models may aid in extrapolating the known efficacy and safety in the non-obese population to the
      obese population.
    • The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients
      Before and One Year After Bariatric Surgery.
    • Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 11/12

      41.

    • Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 12/12

Rokit Healthcare Scores High Marks in KOSDAQ Tech Listing Evaluation

Retrieved on: 
Monday, February 5, 2024

SEOUL, South Korea, Feb. 5, 2024 /PRNewswire/ -- Rokit Healthcare, a trailblazer in AI-driven medical bioprinting technology, proudly announces its achievement of an AA rating in the KOSDAQ (Korea Securities Dealers Automated Quotations) technology listing evaluation.

Key Points: 
  • SEOUL, South Korea, Feb. 5, 2024 /PRNewswire/ -- Rokit Healthcare, a trailblazer in AI-driven medical bioprinting technology, proudly announces its achievement of an AA rating in the KOSDAQ (Korea Securities Dealers Automated Quotations) technology listing evaluation.
  • The evaluation agencies underscored Rokit Healthcare's robust technical capabilities and promising commercial potential, particularly lauding its flagship technology, "AI-based hyper-personalized organ regenerative bioprinting."
  • Commenting on this achievement, Seokhwan Yoo, CEO of Rokit Healthcare, stated, "This successful evaluation validates the significance of Rokit Healthcare's technology and business outlook.
  • We are dedicated to leveraging our KOSDAQ listing to expedite global market expansion and provide patients with innovative treatment alternatives."

Rokit Healthcare Scores High Marks in KOSDAQ Tech Listing Evaluation

Retrieved on: 
Monday, February 5, 2024

SEOUL, South Korea, Feb. 5, 2024 /PRNewswire/ -- Rokit Healthcare, a trailblazer in AI-driven medical bioprinting technology, proudly announces its achievement of an AA rating in the KOSDAQ (Korea Securities Dealers Automated Quotations) technology listing evaluation.

Key Points: 
  • SEOUL, South Korea, Feb. 5, 2024 /PRNewswire/ -- Rokit Healthcare, a trailblazer in AI-driven medical bioprinting technology, proudly announces its achievement of an AA rating in the KOSDAQ (Korea Securities Dealers Automated Quotations) technology listing evaluation.
  • The evaluation agencies underscored Rokit Healthcare's robust technical capabilities and promising commercial potential, particularly lauding its flagship technology, "AI-based hyper-personalized organ regenerative bioprinting."
  • Commenting on this achievement, Seokhwan Yoo, CEO of Rokit Healthcare, stated, "This successful evaluation validates the significance of Rokit Healthcare's technology and business outlook.
  • We are dedicated to leveraging our KOSDAQ listing to expedite global market expansion and provide patients with innovative treatment alternatives."

Slendacor® Weight Management Complex Granted Patent for Research on Thermogenic Benefits

Retrieved on: 
Monday, January 8, 2024

MORRISTOWN, N.J., Jan. 8, 2024 /PRNewswire/ -- PLT Health Solutions, Inc. announced that Slendacor® Weight Management Complex has added to its intellectual property portfolio with a recently granted patent related to new clinical work that studied mechanisms of action behind its weight loss and body shaping benefits, and which demonstrated thermogenic benefits. The invention cited in the patent relates to Slendacor's ability to increase lean body mass and accelerate the conversion of white adipose tissue to the more metabolically active brown or 'beige' adipose tissue. The Japanese patent was part of a global patent initiative by PLT and innovation partner Laila Nutraceuticals and is the first country patent granted as part of a PCT filing across multiple markets. Slendacor is also marketed as Slimvance® in select markets.

Key Points: 
  • MORRISTOWN, N.J., Jan. 8, 2024 /PRNewswire/ -- PLT Health Solutions, Inc. announced that Slendacor® Weight Management Complex has added to its intellectual property portfolio with a recently granted patent related to new clinical work that studied mechanisms of action behind its weight loss and body shaping benefits, and which demonstrated thermogenic benefits.
  • The Japanese patent was part of a global patent initiative by PLT and innovation partner Laila Nutraceuticals and is the first country patent granted as part of a PCT filing across multiple markets.
  • Our customers can be confident of the groundbreaking benefits and efficacy they can offer consumers with Slendacor," he added.
  • Consistent body weight reductions were observed throughout the 16-week trial – starting with statistically significant weight loss at two weeks.

FormaPath announces clinical research and development collaboration with University at Buffalo Center for Advanced Technology

Retrieved on: 
Wednesday, January 3, 2024

ITHACA, N.Y., Jan. 3, 2024 /PRNewswire/ -- FormaPath joins with the University at Buffalo Center for Advanced Technology in Big Data and Health Sciences (UB CAT) to announce their collaboration to further test and develop AdiPress, an automated lymph node dissection device.

Key Points: 
  • ITHACA, N.Y., Jan. 3, 2024 /PRNewswire/ -- FormaPath joins with the University at Buffalo Center for Advanced Technology in Big Data and Health Sciences (UB CAT) to announce their collaboration to further test and develop AdiPress, an automated lymph node dissection device.
  • It is FormaPath's vision that in the future, automated preparation and AI review of tissue will be a fully integrated process.
  • The creation of this database serves as the starting point for assessing the impact of automated preparation on AI-driven diagnostics.
  • We are thrilled to work with Dr. Tomaszewski– and his team on this important study", according to Ted Snelgrove, CEO at FormaPath.